Huan Wang

Huan Wang

Auto-generated profile, based on publicly available information

Huan Wang

Department of Endocrinology and Metabolism, First Hospital of Jilin University, Changchun Jilin, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2019 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
CSChenglin Sun
Chenglin Sun
LSLin Sun
Lin Sun
SXShugang Xi
Shugang Xi
HZHong Zhang
Hong Zhang
HWHuan Wang
Huan Wang
GWGuixia Wang
Guixia Wang
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: By reviewing the previous research of telemedicine, we have found out that old diabetic patients have difficulties in using computers, so it is unrealistic for medical teams to communicate with old diabetes patients anytime and anywhere. However, the popularity of smartphones and chatting applications has enabled old people of China to develop skills of chatting on smartphones and become familiar with smartphone operations. Therefore, we have designed an Mobile Health (m-Health) system for diabetics based on smartphones, which greatly streamlined operation interface and functions for maximum automation. In addition, the smartphone-based telemedicine of diabetes has been designed for old people. Objective: To investigate smartphone-based telemedicine applications in the management of older Chinese patients with type 2 diabetes mellitus (T2DM). Variables of interest included efficacy and safety. Methods: A total of 91 older (age>65) patients with T2DM, who presented to our department, were included and randomly assigned to one of two groups. Patients in the intervention group (n=44) were given glucometers capable of data transmission, and received advice pertaining to medications, diet, and exercise via a Mobile Health(m-Health)telemedicine system. Patients assigned to the control group (n=47) presented to traditional outpatient clinics for their medical care and received no other interventions. We followed up patients in both groups at regular 3-month intervals. Results: After 3 months, patients in the intervention group had significant (P<0.05) improvements in postprandial plasma glucose levels. After 6 months, patients in the intervention group exhibited decreasing trends in postprandial plasma glucose and glycosylated hemoglobin (HbA1C) levels compared with the baseline and those in the control group (P<0.05). Conclusions: Smartphone-based telemedicine applications are effective for controlling blood glucose and lowering HbA1C in older Chinese patients with T2DM. Clinical Trial: The ethics committee of the First Affiliated Hospital of Jilin University approved this study, and has been registered at the China Clinical Trial Registration Center with a registration number of ChiCTR1800015214.

29 September 2021 in Primary Health Care Research & Development
Verified
Journal Article
Open access
PDF file
HWHuan Wang
Huan Wang
XYXiaojie Yuan
Xiaojie Yuan
JWJiping Wang
Jiping Wang
CSChenglin Sun
Chenglin Sun
GWGuixia Wang
Guixia Wang
Aim: Based on the development of telemedicine and the experience of using it during the COVID-19 epidemic, we aimed to explore its convenience and shortcomings to provide a reference for the further improvement of telemedicine. Background: Traditional healthcare has been significantly affected by the outbreak of COVID-19, which has increased fear in patients with chronic diseases and increased the difficulty of obtaining hospitalized treatment. Methods: This is a conceptual article. The literature search is based on Pubmed, including articles published between January 2015 and December 2020. The purpose was to determine whether telemedicine is effective in the management of chronic diseases in the epidemic situation and to develop telemedicine and chronic disease management for long-term epidemic situations in the future. Findings: Telemedicine has demonstrated its advantages during the COVID-19 epidemic and can provide diversified clinical care services for patients with chronic diseases; these services have played a vital role in epidemic prevention and control, greatly alleviated the shortage of medical resources, increased the utilization level of medical resources, and reduced the cross-infection risk during treatment in hospitals. Furthermore, the epidemic situation presents opportunities for the development of diagnosis and treatment methods via the internet and active health management modalities.

29 April 2019 in JMIR Preprints
Verified
Preprint
Open access
CSChenglin Sun
Chenglin Sun
LSLin Sun
Lin Sun
ZLZhuo Li
Zhuo Li
HWHuan Wang
Huan Wang
HWHeyuan Wang
Heyuan Wang
GWGuixia Wang
Guixia Wang
UNSTRUCTURED With the rapid development and spread of information technology, mobile (M)-healthcare is emerging as a feasible option for improved monitoring and treatment of patients with chronic diseases such as diabetes, particularly for patients with limited access to medical institutions. Our study group has developed and evaluated a M-healthcare system that provides remote guidance for diabetic patients. This paper introduces the diabetic M-healthcare system and describes progress in implementation for remote and mobile healthcare in China. We provide evidence that this system improves diabetic patient management and can contribute to the establishment of a new model for patient-centered mobile healthcare.

1 April 2018 in JMIR Preprints
Verified
Preprint
Open access
CSChenglin Sun
Chenglin Sun
LSLin Sun
Lin Sun
SXShugang Xi
Shugang Xi
HZHong Zhang
Hong Zhang
HWHuan Wang
Huan Wang
GWGuixia Wang
Guixia Wang
BACKGROUND Previous studies on telemedicine interventions have shown that older diabetic patients experience difficulty in using computers, which is a barrier to remote communication between medical teams and older diabetic patients. However, older people in China tend to find it easy to use mobile phones and personal messaging apps that have a user-friendly interface. Therefore, we designed a mobile health (mHealth) system for older people with diabetes that is based on mobile phones, has a streamlined operation interface, and incorporates maximum automation. OBJECTIVE The goal of the research was to investigate the use of mobile phone–based telemedicine apps for management of older Chinese patients with type 2 diabetes mellitus (T2DM). Variables of interest included efficacy and safety. METHODS A total of 91 older (aged over 65 years) patients with T2DM who presented to our department were randomly assigned to one of two groups. Patients in the intervention group (n=44) were provided glucometers capable of data transmission and received advice pertaining to medication, diet, and exercise via the mHealth telemedicine system. Patients assigned to the control group (n=47) received routine outpatient care with no additional intervention. Patients in both groups were followed up at regular 3-month intervals. RESULTS After 3 months, patients in the intervention group showed significant (P<.05) improvement in postprandial plasma glucose level. After 6 months, patients in the intervention group exhibited a decreasing trend in postprandial plasma glucose and glycated hemoglobin levels compared with the baseline and those in the control group (P<.05). CONCLUSIONS Mobile phone–based telemedicine apps help improve glycemic control in older Chinese patients with T2DM. CLINICALTRIAL China Clinical Trial Registration Center ChiCTR 1800015214; http://www.chictr.org.cn/showprojen.aspx?proj=25949 (Archived by WebCite at http://www.webcitation.org/73wKj1GMq).